A Pilot Study of Perillyl Alcohol in Pancreatic Cancer
Authors:
- C. Max SchmidtCSC. Max Schmidt
- Howard J. ThomasHTHoward J. Thomas
- Oscar W. CummingsOCOscar W. Cummings
- Eric A. WiebkeEWEric A. Wiebke
- James A. MaduraJMJames A. Madura
- Loehrer J. PatrickLPLoehrer J. Patrick
- P.L. CrowellPCP.L. Crowell
- 1 June 2008
- journal article
- clinical trial
- Published by Elsevier in Journal of Surgical Research
- Vol. 147 (2) , 194-199
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 daysCancer Chemotherapy and Pharmacology, 2004
- Phase I trial of perillyl alcohol administered four times daily continuouslyCancer Chemotherapy and Pharmacology, 2003
- Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancerInvestigational New Drugs, 2003
- A phase I trial of perillyl alcohol in patients with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2003
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Phase I Study of Perillyl Alcohol in Patients with Refractory MalignanciesCancer Biology & Therapy, 2002
- Phase II Trial of Perillyl Alcohol in Patients with Metastatic Colorectal CancerJournal of Gastrointestinal Cancer, 2002
- Induction of the apoptosis-promoting protein Bak by perillyl alcohol in pancreatic ductal adenocarcinoma relative to untransformed ductal epithelial cellsCarcinogenesis, 1997
- Chemotherapy of pancreatic cancer with the monoterpene perillyl alcoholCancer Letters, 1995
- Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferationBiochemical Pharmacology, 1994